Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methimazole
Drug ID BADD_D01414
Description Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.[A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949[A184502] and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive options such as surgery or radioactive iodine therapy are inappropriate.[L8336,L8339] On a weight basis, methimazole is 10 times more potent than the other major antithyroid thionamide used in North America, [propylthiouracil],[L8339] and is the active metabolite of the pro-drug [carbimazole], which is an antithyroid medication used in the United Kingdom and parts of the former British Commonwealth.[A184733] Traditionally, methimazole has been preferentially used over propylthiouracil due to the risk of fulminant hepatotoxicity carried by the latter,[A184757] with propylthiouracil being preferred in pregnancy due to a perceived lower risk of teratogenic effects. Despite documented teratogenic effects in its published labels,[L8336,L8339] the true teratogenicity of methimazole appears to be unclear[A184643,A184757,A184763] and its place in therapy may change in the future.
Indications and Usage In the United States, methimazole is indicated for the treatment of hyperthyroidism in patients with Graves' disease or toxic multinodular goiter for whom thyroidectomy or radioactive iodine therapy are not appropriate treatment options. Methimazole is also indicated for the amelioration of hyperthyroid symptoms in preparation for thyroidectomy or radioactive iodine therapy.[L8336] In Canada, methimazole carries the above indications and is also indicated for the medical treatment of hyperthyroidism regardless of other available treatment options.[L8339]
Marketing Status approved
ATC Code H03BB02
DrugBank ID DB00763
KEGG ID D00401
MeSH ID D008713
PubChem ID 1349907
TTD Drug ID D0S4BR
NDC Product Code 63629-2225; 63629-8347; 70518-1506; 60687-357; 63629-2224; 63629-4331; 68788-8227; 72162-1803; 23155-070; 60429-381; 62135-206; 63629-6408; 63629-9137; 63629-9251; 64380-212; 64380-213; 54382-112; 62135-205; 63629-9249; 63629-9250; 62991-1515; 51927-1943; 49884-640; 70518-1475; 60687-669; 60687-680; 51552-0822; 33342-335; 60687-370; 64980-265; 68071-5197; 72162-1802; 66219-0253; 33342-336; 49884-641; 50090-6536; 64980-264; 68788-8226; 71335-0883; 38779-0360; 70160-001; 70600-032; 23155-071
UNII 554Z48XN5E
Synonyms Methimazole | 1-Methyl-2-mercaptoimidazole | 1 Methyl 2 mercaptoimidazole | Merkazolil | Tiamazol | Thiamazole | Thimazol | Mercasolyl | Mercazolyl | Methymazol | Methylmercaptoimidazole | Mercazol | Mercazole | Metisol | Metizol | Tapazole | Tirodril | Strumazol | Thiamazol Henning | Henning, Thiamazol | Thiamazol Hexal | Hexal, Thiamazol | Thyrozol | Favistan | Methizol
Chemical Information
Molecular Formula C4H6N2S
CAS Registry Number 60-56-0
SMILES CN1C=CNC1=S
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diarrhoea07.02.01.001--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.000202%Not Available
Drug hypersensitivity10.01.01.0010.002366%Not Available
Dyspepsia07.01.02.001--
Dyspnoea22.02.01.004; 02.11.05.003--
Encephalopathy17.13.02.0010.000202%
Fatigue08.01.01.002--
Febrile neutropenia08.05.02.004; 01.02.03.0020.000910%
Flatulence07.01.04.0020.000202%
Glomerulonephritis20.05.01.001; 10.02.01.0060.000202%Not Available
Goitre14.11.01.008; 05.02.01.0010.000202%Not Available
Granulocytopenia01.02.03.003--Not Available
Guillain-Barre syndrome17.09.01.001; 11.07.01.001; 10.04.10.0050.000506%
Haematochezia24.07.02.012; 07.12.02.003--Not Available
Haemolytic anaemia01.06.03.0020.000303%Not Available
Headache17.14.01.001--
Hepatic encephalopathy17.13.01.003; 09.01.03.0060.000202%Not Available
Hepatic failure09.01.03.0020.000303%
Hepatitis09.01.07.004--Not Available
Hepatitis cholestatic09.01.01.0020.000607%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.000303%Not Available
Hyperammonaemia14.10.01.001; 09.01.02.0020.000202%Not Available
Hypersensitivity vasculitis24.12.04.013; 23.06.02.005; 10.02.02.017; 01.01.04.0080.000607%Not Available
Hyperthyroidism14.11.01.011; 05.02.02.0010.001658%
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.000202%
Hypoglycaemic coma17.02.09.005; 14.06.03.004; 05.06.03.004--Not Available
Hypoprothrombinaemia01.01.01.001--Not Available
Hypothyroidism14.11.01.012; 05.02.03.0010.002326%
Insulin autoimmune syndrome10.04.08.005; 05.06.01.007; 14.06.01.0070.000303%Not Available
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene